Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

and the obesity pill race. Mizuo healthcare strategist Jared Holtz joins us here on the set. You know, beyond just the patients being nauseous, investors are too today, down 42%.Is this it. I mean, are they done. Is Viking Therapeutics out of this race for the obesity pill.>> I don't think they're done. I mean, it's a it's a big setback for sure. It's going to come down to what the next trial looks like, what the dosing is, but this sort of discontinuation rate when you have monster companies that are ahead ...